Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Post-essential thrombocythaemia myelofibrosis, Post-polycythaemia vera myelofibrosis, Primary myelofibrosis Age: Adult Condition: Platelet count greater than 200,000/mm3 |
Dose: Oral – 20 mg Frequency: twice daily Note: Initial dose. Titrate doses based on efficacy and tolerability. Maximum: 25 mg twice daily. Dose may be reduced if platelet is less than 100,000/mm3. Discontinue if platelet count is less than 50,000/mm3 or absolute neutrophil count less than 500/mm3. Discontinue if there is no improvement in symptoms or reduction in spleen size after 6 months. |
|
Indication: Post-essential thrombocythaemia myelofibrosis, Post-polycythaemia vera myelofibrosis, Primary myelofibrosis Age: Adult Condition: Platelet count 100,000-200,000/mm3 |
Dose: Oral – 15 mg Frequency: twice daily Note: Initial dose. Titrate doses based on efficacy and tolerability. Maximum: 25 mg twice daily. Dose may be reduced if platelet is less than 100,000/mm3. Discontinue if platelet count is less than 50,000/mm3 or absolute neutrophil count less than 500/mm3. Discontinue if there is no improvement in symptoms or reduction in spleen size after 6 months. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Graft versus Host Disease Age: less than 12 years |
Dose: Oral dose Note: Safety and efficacy not established |
|
Indication: Acute Graft versus Host Disease Age: greater than 12 years Condition: Initial dose |
Dose: Oral Tablet – 5 mg Frequency: twice daily Note: by mouth (oral); may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts have not decreased by ?50% compared to baseline |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Myelofibrosis Condition: Moderate-to-severe renal impairment (Creatinine Clearance 15-59 mL/minute) and Platelet count greater than 150 x10^9/L |
Dose: Tablet – No dosage adjustment necessary Note: Starting dose |
|
Indication: Myelofibrosis Condition: Moderate-to-severe renal impairment (Creatinine Clearance 15-59 mL/minute) and Platelet count 100-150 x10^9/L |
Dose: Tablet – 10 mg Frequency: twice daily Note: Starting dose |
Administration
- May be taken with or without food
- Take at same time each day
Side Effect
- Anemia (96.1%)
- Thrombocytopenia (69.7%)
- Increased ALT, grade 1 (25.2%)
- Bruising (23.2%)
- Neutropenia (18.7%)
- Dizziness (18.1%)
- Increased AST, grade 1 (17.1%)
- Increased cholesterol, grade 1 (16.8%)
- Headache (14.8%)
- (GvHD) Anemia (75%) Thrombocytopenia (75%)
- Thrombocytopenia, Grade 3-4 (61%)
- Neutropenia (58%)
- Infections (55%)
- Edema (51%)
- Hemorrhage (49%)
- Anemia, Grade 3-4 (45%)
- Infections, Grade 3-4 (41%)
- Neutropenia (40%)
- Elevated ALT/AST (48%) Fatigue (37%)
- Bacterial infections (32%)
- Bacterial infections, Grade 3-4 (28%)
- Hemorrhage, Grade 3-4 (20%)
- Fatigue, Grade 3-4 (14%)
- Edema, Grade 3-4 (13%)
- Hypertriglyceridemia (11%)
- (MF and PV) Urinary Tract Infection (UTI) (9%)
- Weight gain (7.1%)
- Flatulence (5.2%)
- Herpes zoster (1.9%)
- (GvHD) Elevated ALT/AST, Grade 3-4 (6-8%)
- Hypertriglyceridemia, Grade 3-4 (1%)
- Increased AST, grade 2 (0.6%)
- Increased cholesterol, grade 2 (0.6%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)
|
Increased plasma concentration
|
|
Mild or moderate CYP3A4 inhibitors (e.g. ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine)
|
Increased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Do not store above 30°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.